How to Help Your Patients Find Entyvio in Stock: A Provider's Guide

Your patient is stable on Entyvio (Vedolizumab). Their Crohn's disease or ulcerative colitis is well-controlled. Then the call comes: the specialty pharmacy can't fill the prescription, or the infusion center doesn't have stock. Now you're managing a clinical problem that has nothing to do with the medicine itself.

This scenario is increasingly common for providers managing IBD patients on Entyvio. While not in official shortage, access challenges are real. This guide offers a practical, step-by-step approach to helping your patients maintain continuity of care with Entyvio in 2026.

Current Availability Landscape

Entyvio is manufactured exclusively by Takeda Pharmaceuticals and distributed through specialty channels. Key facts for 2026:

• No FDA-listed shortage as of March 2026
• No biosimilars available — earliest projected entry is 2028-2032
• Two formulations: IV infusion (300 mg) and SC injection (108 mg Entyvio Pen)
• Global revenue ~$6.4 billion in 2025 — indicating high demand worldwide
• Distribution limited to specialty pharmacies, infusion centers, and hospital pharmacies

Availability can vary significantly by region, by specialty pharmacy vendor, and even by week. The patients most affected are those newly initiating therapy (who need timely induction dosing) and those whose insurance or specialty pharmacy arrangements change mid-treatment.

Why Patients Can't Find Entyvio

Understanding the root causes helps you address them systematically:

1. Specialty distribution bottlenecks: Entyvio doesn't flow through retail pharmacy channels. Specialty pharmacies may need to special-order each patient's supply, and lead times can vary.
2. Insurance and prior authorization delays: Coverage gaps during authorization renewals or plan changes can create the appearance of unavailability when the real issue is reimbursement.
3. Infusion center capacity: For IV Entyvio, chair availability at infusion centers can be a limiting factor, particularly in high-demand areas.
4. Single-source supply: With no biosimilar competition, any Takeda manufacturing constraint affects the entire market.
5. Patient confusion: Many patients don't understand the specialty pharmacy process and may search retail pharmacies or delay action until their next dose is overdue.

What Providers Can Do: 5 Practical Steps

Step 1: Verify Availability Before Prescribing

Before writing a new Entyvio prescription or continuing an existing one, proactively verify that the patient's specialty pharmacy or infusion center has stock. This is especially critical for new starts, where timely induction at weeks 0, 2, and 6 is essential for therapeutic response.

Use Medfinder for Providers to check real-time Entyvio availability at specialty pharmacies and infusion centers in your patient's area. This takes seconds and can prevent a multi-week scramble after the prescription is already written.

Step 2: Establish Multiple Pharmacy and Infusion Center Relationships

Don't rely on a single specialty pharmacy or infusion center. Establish working relationships with at least 2-3 options in your area. Consider:

• National specialty pharmacies (e.g., Optum Specialty, CVS Specialty, Accredo)
• Regional and independent specialty pharmacies — often more agile in sourcing hard-to-find medications
• Hospital-based outpatient infusion centers
• Independent infusion centers — may have more scheduling flexibility
• In-office infusion (buy-and-bill) if your practice has the capability

Having backup options means you can redirect patients quickly when one source is out of stock.

Step 3: Leverage Formulation Flexibility

Both formulations are now approved for UC and CD maintenance:

• IV infusion (300 mg every 8 weeks): Supervised, ensures adherence, requires infusion center access
• SC pen (108 mg every 2 weeks): Home self-administration, may be sourced through mail-order specialty pharmacies

If a patient's infusion center is booked or out of stock, consider transitioning to SC maintenance. Conversely, if the SC pen is backordered through a patient's specialty pharmacy, IV infusion may be available at a different site.

Note: Induction must still be completed via IV infusion (300 mg at weeks 0, 2, and 6) before transitioning to SC maintenance.

Step 4: Engage EntyvioConnect Early

Takeda's EntyvioConnect program (1-844-368-9846) is a valuable resource that goes beyond copay cards:

• Benefits verification: Helps confirm coverage before treatment starts
• Prior authorization support: Assists with documentation and submission
• Supply coordination: Can help locate stock and coordinate with specialty pharmacies
• Copay assistance: Eligible commercially insured patients may pay $0 per dose
• Patient Assistance Program: Free medication for uninsured or coverage-denied patients

Engaging EntyvioConnect at the time of prescribing — not after a problem arises — can prevent many access issues.

Step 5: Educate Your Patients

Proactive patient education reduces crisis calls and treatment gaps:

• Explain that Entyvio is a specialty medication with a different distribution process than standard prescriptions
• Set expectations for processing time — specialty pharmacy orders can take 5-10 business days
• Instruct patients to start refill processes at least 2 weeks before their next dose is due
• Share Medfinder as a tool they can use independently to check availability
• Provide the EntyvioConnect phone number (1-844-368-9846) for questions about access and copay support

When to Consider Alternatives

If Entyvio access is consistently unreliable for a given patient, consider whether an alternative biologic may provide more dependable access. Options include:

• Humira (Adalimumab) or biosimilars: TNF-alpha inhibitor; SC injection; biosimilars widely available at lower cost
• Stelara (Ustekinumab): IL-12/23 inhibitor; IV induction then SC maintenance; biosimilars entering market
• Skyrizi (Risankizumab): IL-23 inhibitor; IV induction then SC maintenance; strong efficacy data for UC and CD
• Rinvoq (Upadacitinib): JAK inhibitor; oral tablet; convenient but carries boxed warning for serious cardiovascular, thrombotic, and malignancy risks

The clinical decision to switch should weigh the patient's treatment history, disease severity, prior biologic exposure, and individual risk factors. For a detailed comparison, see Alternatives to Entyvio.

Workflow Tips for Your Practice

Integrating supply awareness into your clinical workflow can prevent most access disruptions:

• At the prescribing visit: Verify availability via Medfinder, initiate prior authorization, and enroll the patient in EntyvioConnect
• Before each infusion/refill: Have staff confirm stock with the specialty pharmacy or infusion center 7-10 days in advance
• When issues arise: Check alternative sources immediately rather than waiting. The sooner you act, the less likely the patient will miss a dose.
• Track supply patterns: If a particular pharmacy or infusion center consistently has issues, shift patients to more reliable sources
• Document everything: If a patient misses a dose due to supply, document the reason and clinical impact. This can support appeals and alternative authorization requests.

Final Thoughts

Keeping patients on Entyvio requires more than good prescribing — it requires proactive supply management. In a market with a single manufacturer, no biosimilars, and specialty distribution, access challenges are a clinical reality that demands a systematic approach.

Tools like Medfinder for Providers and programs like EntyvioConnect are designed to help. Integrate them into your workflow, establish backup pharmacy and infusion relationships, and educate your patients to be proactive about their own access.

Related resources:

• Entyvio Shortage: What Providers Need to Know in 2026
• How to Help Patients Save Money on Entyvio
• Entyvio Drug Interactions: What to Avoid
• How Does Entyvio Work? Mechanism of Action Explained